{"product_id":"srpt-business-model-canvas","title":"(SRPT) Sarepta Therapeutics, Inc. Business Model Canvas Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta’s Rare Disease Business Model, Unpacked\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Sarepta Therapeutics, Inc.'s business model. This concise Business Model Canvas shows how the company creates value in rare disease therapies, builds key partnerships, and drives revenue through specialized biotech innovation. Ideal for investors, analysts, and strategists who want actionable insight—download the full version to go deeper.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePartnerships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eF. Hoffmann-La Roche Ltd collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eF. Hoffmann-La Roche Ltd gives Sarepta a global pharma partner with ex-U.S. reach for genetic medicine, helping expand commercialization beyond Sarepta’s U.S. base. The tie-up also shares clinical, regulatory, and manufacturing risk; Roche paid $1.15 billion upfront, with up to $1.7 billion in milestones tied to the collaboration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNationwide Children’s Hospital research tie-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNationwide Children’s Hospital gives Sarepta access to pediatric neuromuscular expertise that helps shape trial design, find patients, and speed translational research for childhood-onset rare diseases. This matters for Duchenne muscular dystrophy, which affects about 1 in 3,500 male births and needs early, specialized care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLysogene and Duke University collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLysogene and Duke University give Sarepta Therapeutics, Inc. academic depth in gene therapy and rare disease biology, which helps validate targets, build datasets, and speed early-stage work. In 2025, Sarepta had 1 approved gene therapy and multiple RNA-based programs in its pipeline, so outside research links help widen its innovation base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGenethon gene therapy collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenethon brings AAV vector design and gene-therapy know-how that helps Sarepta Therapeutics, Inc. advance muscular dystrophy programs; the tie-up supports platform learning and CMC scale-up, which matter in an area where Sarepta reported 2024 revenue of $1.95 billion and kept R\u0026amp;D spending near $716 million.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAAV vector and process know-how\u003c\/li\u003e\n\u003cli\u003eSupports muscular dystrophy programs\u003c\/li\u003e\n\u003cli\u003eHelps manufacturing scale learning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStrideBio capsid and vector technology partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrideBio gives Sarepta Therapeutics, Inc. capsid and vector engineering tools for gene therapy delivery, so Sarepta can tap differentiated platforms without building every system in-house. That kind of partner access can shorten development cycles and widen technical options across programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess to StrideBio gene therapy tools\u003c\/li\u003e\n\u003cli\u003eSupports vector engineering and delivery\u003c\/li\u003e\n\u003cli\u003eReduces internal platform build time\u003c\/li\u003e\n\u003cli\u003eExpands technical optionality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta’s Big-Deal Gene Therapy Bet with Roche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. leans on Roche, Nationwide Children’s, Lysogene, Duke, Genethon, and StrideBio to share clinical risk, extend ex-U.S. reach, and speed gene-therapy and rare-disease R\u0026amp;D. In 2025, it had 1 approved gene therapy; Roche paid $1.15 billion upfront, plus up to $1.7 billion in milestones.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoche\u003c\/td\u003e\n\u003ctd\u003e$1.15B upfront; up to $1.7B milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSarepta pipeline\u003c\/td\u003e\n\u003ctd\u003e1 approved gene therapy in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, real-world Business Model Canvas of Sarepta Therapeutics, Inc., covering its 9 blocks, strategy, and biotech market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eClarifies Sarepta Therapeutics’ business model in a simple canvas, helping teams quickly spot pain points and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eSarepta Therapeutics, Inc. Reference Sources give a clear, credible trail that supports faster due diligence and better decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eActivities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNA-targeted therapeutic discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. centers RNA-targeted discovery on mutation-specific target selection and oligonucleotide design for rare genetic diseases, especially Duchenne muscular dystrophy. Its platform has already yielded 3 FDA-approved exon-skipping medicines for Duchenne, and this work remains the core of its RNA strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene therapy program development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. advances gene therapy programs such as Elevidys (SRP-9001), the first FDA-approved gene therapy for Duchenne muscular dystrophy, and SRP-9003 for limb-girdle muscular dystrophy. This work covers vector design, preclinical testing, and trial execution, alongside oligonucleotide medicines that helped drive about $1.8 billion in 2024 revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development and trial operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta runs genetically targeted trials in rare neuromuscular disease, with protocol design, site management, recruitment, and endpoint analysis built around its 3 FDA-approved therapies. These studies support regulatory approval and label expansion, where small patient pools and strict endpoints make trial execution a core value driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory filings and lifecycle management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. runs a heavy regulatory load because its Duchenne pipeline and marketed therapies sit in accelerated-approval settings, where post-launch evidence matters as much as the original filing. The company has 4 FDA-approved DMD therapies, so lifecycle management covers safety reports, label changes, and confirmatory data for each product.\u003c\/p\u003e\n\u003cp\u003eThat work spans U.S. and ex-U.S. submissions, plus ongoing evidence generation after launch. In rare disease, a single adverse-event trend or failed follow-up study can shift revenue fast, so regulatory execution is a core operating skill, not just a compliance task.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 FDA-approved Duchenne therapies\u003c\/li\u003e\n\u003cli\u003eU.S. and ex-U.S. filings\u003c\/li\u003e\n\u003cli\u003eSafety and label updates\u003c\/li\u003e\n\u003cli\u003ePost-launch evidence generation\u003c\/li\u003e\n\u003cli\u003eCritical in accelerated approval\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing and quality control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. has to make complex oligonucleotides and gene therapy materials under GMP rules, where batch release testing and tight process control decide whether supply reaches patients on time. That matters more here because its injectable and gene-based products depend on strong quality systems to protect safety and avoid costly lot failures.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRun GMP manufacturing with strict controls\u003c\/li\u003e\n\u003cli\u003eTest every batch before release\u003c\/li\u003e\n\u003cli\u003eProtect supply continuity across sites\u003c\/li\u003e\n\u003cli\u003eKeep quality systems audit-ready\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta: 4 DMD Therapies, 3 Exon-Skipping Drugs, $1.8B Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. focuses on RNA drug design, gene therapy development, and rare-disease trials, with 4 FDA-approved Duchenne muscular dystrophy therapies and 3 exon-skipping medicines. It also runs GMP manufacturing and post-launch regulatory work to keep supply, safety, and label updates on track.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDMD therapies\u003c\/td\u003e\n\u003ctd\u003e4 approved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExon-skipping medicines\u003c\/td\u003e\n\u003ctd\u003e3 approved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThis Sarepta Therapeutics, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase. It’s not a sample or placeholder—what you see here is a direct snapshot of the final file. Once ordered, you’ll get the same professionally formatted document in full.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eResources\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApproved Duchenne therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEXONDYS 51 and VYONDYS 53 are Sarepta Therapeutics, Inc. commercial DMD assets for the ~13% of patients amenable to exon 51 skipping and the ~8% amenable to exon 53 skipping. Together, they anchor the rare-disease revenue base and give Sarepta Therapeutics, Inc. long-running real-world clinical and commercial data from approved Duchenne therapy use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMutation-specific exon-skipping know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. owns hard-to-copy PMO chemistry and mutation-specific exon-skipping know-how, backed by 3 U.S.-approved Duchenne muscular dystrophy exon-skipping drugs: Exondys 51, Vyondys 53, and Amondys 45. That IP base feeds its RNA-targeted pipeline and keeps its DMD position differentiated, because matching a single-variant program takes years of chemistry, data, and regulatory work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene therapy pipeline assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. relies on two major gene therapy pipeline assets, SRP-9001 and SRP-9003, as core growth options beyond its exon-skipping portfolio. These programs expand the Company Name’s reach across muscular dystrophy subtypes and support a broader neuromuscular franchise, with gene therapy adding a higher-value path than single-exon correction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRare disease clinical and natural-history data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRare-disease clinical and natural-history data are a core asset for Sarepta Therapeutics, Inc. because Duchenne affects about 1 in 3,500 to 5,000 male births, so patient-specific datasets matter when endpoints are scarce and small cohorts must be stratified. Natural-history and biomarker data help shape trial design, support FDA interactions, and better target patients most likely to respond.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall cohorts need patient-level data.\u003c\/li\u003e\n\u003cli\u003eBiomarkers support trial design.\u003c\/li\u003e\n\u003cli\u003eData sharpens patient targeting.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialized scientific and regulatory talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. relies on teams with deep genetics, oligonucleotide, gene therapy, and rare-disease regulatory skills. That human capital is key in a market with 4 FDA-approved Duchenne therapies, because it drives discovery, speeds review, and supports commercialization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDeep genetics and gene-therapy expertise\u003c\/li\u003e\n\u003cli\u003eRare-disease regulatory execution\u003c\/li\u003e\n\u003cli\u003eTurns science into approved products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta’s Rare-Disease Moat: Approved Drugs, IP, and Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. key resources are its 3 FDA-approved Duchenne exon-skipping drugs, PMO chemistry IP, and gene-therapy pipeline. These assets support a rare-disease franchise for about 1 in 3,500 to 5,000 male births and keep the Company Name’s science hard to copy.\u003c\/p\u003e\n\u003cp\u003eIts data set also matters: long-term clinical, natural-history, and biomarker evidence helps shape trials and FDA work in small, genotype-based groups.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved DMD therapies\u003c\/td\u003e\n\u003ctd\u003e3 products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExon 51 \/ 53 reach\u003c\/td\u003e\n\u003ctd\u003e~13% \/ ~8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDMD incidence\u003c\/td\u003e\n\u003ctd\u003e1 in 3,500-5,000 male births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eValue Propositions\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMutation-specific treatment for DMD exon 51\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEXONDYS 51 gives Sarepta Therapeutics, Inc. a mutation-specific option for Duchenne muscular dystrophy patients with confirmed dystrophin mutations amenable to exon 51 skipping, a group that represents about 13% of DMD cases. That precision fit matters in a rare disease affecting roughly 1 in 3,500 to 5,000 male births, where targeted therapy can be the only genotype-based choice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMutation-specific treatment for DMD exon 53\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVYONDYS 53 is a mutation-specific therapy for Duchenne muscular dystrophy patients with exon 53 skipping mutations, a group that accounts for about 8% of DMD cases. This genotype-linked design supports individualized care, and it fits Sarepta Therapeutics, Inc.’s precision-medicine model rather than broad, one-size-fits-all use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNA-targeted genetic medicine platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. builds its value on RNA-targeted genetic medicine, using exon-skipping and other RNA approaches to treat the root cause of rare diseases rather than only easing symptoms. This focus fits a market where 7,000+ rare diseases are mostly genetic, and it sets Sarepta apart from small-molecule care models built for broader, non-genetic conditions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGene therapy approach for muscular dystrophy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. is building one-time gene therapies for Duchenne muscular dystrophy and limb-girdle muscular dystrophy to fix the root genetic defect, not just treat symptoms. Elevidys, the first FDA-approved gene therapy for Duchenne, gives the model real commercial proof and shifts value toward durable, infrequent dosing instead of lifelong treatment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne-time treatment goal\u003c\/li\u003e\n\u003cli\u003eTargets the genetic cause\u003c\/li\u003e\n\u003cli\u003eExpands value beyond chronic dosing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRare-disease specialist support model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. pairs rare-disease treatment with diagnostic, access, and monitoring support, which is key when patient pools are tiny and reimbursement is slow. In Duchenne muscular dystrophy, where the company had 4 marketed therapies in 2025, this service layer helps patients start therapy and stay on it.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports diagnosis and payer access\u003c\/li\u003e\n\u003cli\u003eTracks patients after start\u003c\/li\u003e\n\u003cli\u003eFits small, complex care paths\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta’s Precision DMD Platform: Four Therapies, One Rare-Disease Edge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. value proposition is mutation-matched Duchenne care: EXONDYS 51 and VYONDYS 53 serve about 13% and 8% of DMD cases, while Elevidys extends the model to one-time gene therapy. In 2025, the company had 4 marketed therapies, reinforcing a platform built on precision, durability, and rare-disease access support.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEXONDYS 51\u003c\/td\u003e\n\u003ctd\u003eAbout 13% of DMD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVYONDYS 53\u003c\/td\u003e\n\u003ctd\u003eAbout 8% of DMD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketed therapies\u003c\/td\u003e\n\u003ctd\u003e4 in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Relationships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetic test driven prescribing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTreatment selection at Sarepta Therapeutics, Inc. starts with confirmed mutation status, so prescribing is tied to genetic evidence and specialist review before exon-skipping therapy is used. Duchenne muscular dystrophy affects about 1 in 3,500 to 5,000 live male births, which makes this test-first model central to reaching the right patients fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuromuscular specialist support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. relies on neuromuscular specialists and clinics to start and monitor therapy in rare muscle disease, especially Duchenne muscular dystrophy, which affects about 1 in 3,500 to 5,000 male births. The relationship is high-touch and clinical because these patients are few, medically complex, and need specialist-led initiation and follow-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient start and reimbursement assistance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. relies on patient start and reimbursement support because rare-disease treatments often need prior authorization, step edits, and payer coordination before treatment begins. That help cuts delays and denials in a market where access can hinge on one approved claim.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLong term therapy monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. must keep patients in long-term contact because Duchenne and other rare neuromuscular diseases need safety, adherence, and outcome tracking after treatment, not just a one-time dispense. This also helps build post-marketing evidence, which is critical when FDA follow-up can run up to 15 years for gene therapy products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrack safety over years, not weeks.\u003c\/li\u003e\n\u003cli\u003eSupport daily adherence in chronic care.\u003c\/li\u003e\n\u003cli\u003eCollect real-world outcome data.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCaregiver centered communication\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCaregiver centered communication is critical at Sarepta Therapeutics, Inc. because Duchenne muscular dystrophy affects about 1 in 3,500 to 5,000 male births, and many patients are children or teens. That means Sarepta Therapeutics, Inc. must educate caregivers on dosing, infusion steps, and monitoring, since missed details can affect safety and adherence in rare disease care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCaregivers help manage pediatric treatment\u003c\/li\u003e\n\u003cli\u003eTeach dosing and infusion logistics\u003c\/li\u003e\n\u003cli\u003eMonitor safety in rare disease use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta’s High-Touch Care Keeps Duchenne Patients Connected\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. keeps customer ties high-touch: neuromuscular specialists confirm mutation status, start therapy, and track safety for years, while caregivers get dosing and infusion help for mostly pediatric Duchenne patients. This matters in a disease seen in about 1 in 3,500 to 5,000 male births.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFocus\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient base\u003c\/td\u003e\n\u003ctd\u003e1 in 3,500-5,000 male births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupport\u003c\/td\u003e\n\u003ctd\u003ePrior auth, training, follow-up\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eChannels\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuromuscular specialty clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuromuscular specialty clinics are Sarepta Therapeutics, Inc.’s key channel because they are where diagnosis and treatment start: Duchenne muscular dystrophy affects about 1 in 3,500 to 5,000 male births, so routing patients through a small number of expert centers speeds genetic testing and therapy uptake.\u003c\/p\u003e\n\u003cp\u003eThese clinics also concentrate specialists, testing labs, and long-term follow-up in one place, which matters in rare disease care where each new patient can move a high-value therapy case into treatment fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital infusion centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospital infusion centers are critical for Sarepta Therapeutics, Inc. because Elevidys is given as a one-time intravenous infusion in a monitored hospital setting, which fits therapies that cannot be taken by mouth and need close safety checks. This channel also suits pediatric and complex-care patients, with 2025 Elevidys sales helping drive Sarepta Therapeutics, Inc. revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty pharmacy distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty pharmacies are the main route for Sarepta Therapeutics, Inc.'s limited-distribution rare disease medicines. They manage cold-chain shipping, prior authorization, and patient onboarding, which is standard for high-cost biologic and gene therapies with tight access controls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eField medical and reimbursement teams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eField medical and reimbursement teams help prescribers, payers, and families move Sarepta Therapeutics, Inc. therapies from evidence to access, which matters in rare disease where the U.S. Duchenne population is about 15,000 to 20,000 and every delayed approval can block treatment. In this channel, education and coverage support can drive uptake as much as promotion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupport access and education\u003c\/li\u003e\n\u003cli\u003eTranslate data into uptake\u003c\/li\u003e\n\u003cli\u003eCritical in rare disease\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical trial site network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. uses academic centers and specialized hospitals as trial hubs to enroll eligible Duchenne patients and collect the clinical data needed for approval and label expansion. This network also keeps the company close to patients before and after launch, while supporting its 4 approved therapies and ongoing pipeline work.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrives pipeline enrollment\u003c\/li\u003e\n\u003cli\u003eGenerates approval data\u003c\/li\u003e\n\u003cli\u003eSupports label expansion\u003c\/li\u003e\n\u003cli\u003eStays close to patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta’s Rare Disease Channels Drive Elevidys Access and Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChannels for Sarepta Therapeutics, Inc. are highly concentrated: neuromuscular clinics, hospital infusion centers, specialty pharmacies, and academic trial sites move rare Duchenne patients from diagnosis to Elevidys and other therapies. With about 15,000 to 20,000 U.S. Duchenne patients and 1-in-3,500 to 5,000 male births affected, each channel directly shapes access, uptake, and 2025 revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eExpert care network\u003c\/td\u003e\n\u003ctd\u003eDiagnosis, infusion, access\u003c\/td\u003e\n\u003ctd\u003e15k-20k U.S. patients; 2025 Elevidys sales driver\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Segments\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetically confirmed DMD patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGenetically confirmed DMD patients are Sarepta Therapeutics, Inc.'s core exon-skipping base: boys and young men with a documented dystrophin gene mutation, not just a clinical DMD diagnosis. The market is rare and narrow; Duchenne affects about 1 in 3,500 to 5,000 male births, and only mutation-defined subsets are eligible for EXONDYS 51, VYONDYS 53, or AMONDYS 45.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExon 51 amenable DMD patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExon 51 amenable DMD patients are the core Customer Segment because their mutation type makes them eligible for EXONDYS 51, Sarepta Therapeutics, Inc.'s marketed exon-skipping therapy. This genetic fit is the main filter, and exon 51 skipping covers about 13% of Duchenne muscular dystrophy cases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExon 53 amenable DMD patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExon 53 amenable DMD patients are a mutation-defined rare-disease segment eligible for VYONDYS 53; Sarepta says exon 53 skipping can apply to about 8% of Duchenne muscular dystrophy patients, a small but commercially important pool. Care is usually coordinated through neuromuscular specialty centers, where diagnosis, genetic testing, and long-term monitoring are concentrated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDMD and LGMD gene therapy candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. targets boys and young men with Duchenne muscular dystrophy, a rare disease that affects about 1 in 3,500 to 5,000 male births, plus limb-girdle muscular dystrophy patients, where subtypes can require separate genetic confirmation. These are future launch pools for its gene therapy pipeline, and they need early mutation testing, biopsy-free genetic screening, and close cardiac and motor monitoring.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDMD: 1 in 3,500–5,000 male births\u003c\/li\u003e\n\u003cli\u003eLGMD: subtype-specific genetic testing\u003c\/li\u003e\n\u003cli\u003eHigh need for long-term monitoring\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNeuromuscular specialists and payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuromuscular specialists drive prescribing in Duchenne and other rare myopathies, while payers decide access and reimbursement; Sarepta’s ELEVIDYS list price was about $3.2 million per patient, so both groups shape uptake. In rare disease, specialists build the treatment case and payers can still block or speed coverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialists influence diagnosis and prescribing\u003c\/li\u003e\n\u003cli\u003ePayers control coverage and reimbursement\u003c\/li\u003e\n\u003cli\u003e$3.2M price raises access hurdles\u003c\/li\u003e\n\u003cli\u003eBoth are critical commercial gatekeepers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta Targets Tiny, High-Value Duchenne Patient Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. serves mutation-defined Duchenne muscular dystrophy segments, led by exon 51 and exon 53 amenable patients who qualify for EXONDYS 51 and VYONDYS 53. The pool is very small: DMD affects about 1 in 3,500–5,000 male births, and exon 51 covers about 13% of cases while exon 53 covers about 8%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExon 51\u003c\/td\u003e\n\u003ctd\u003eAbout 13% of DMD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExon 53\u003c\/td\u003e\n\u003ctd\u003eAbout 8% of DMD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDMD base\u003c\/td\u003e\n\u003ctd\u003e1 in 3,500-5,000 male births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCost Structure\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and development spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResearch and development is Sarepta Therapeutics, Inc. largest long-cycle cost center: the company spent about $1.2 billion on R\u0026amp;D in 2024, driven by discovery, preclinical work, and pipeline advancement across rare-disease genetics and gene therapy. That spend supports its late-stage Duchenne programs and multiple gene therapy assets, so the cost base stays high for years before any payoff.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial execution costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trial execution costs are heavy for Sarepta Therapeutics, Inc. because rare-disease studies need hard-to-find patients, paid sites, close monitoring, and long data follow-up. In 2024, Sarepta spent $1.13 billion on R\u0026amp;D, and its Duchenne gene therapy and exon-skipping programs add extra site, imaging, and safety-review costs that grow as follow-up extends.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and CMC expense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. carries a heavy manufacturing and CMC cost base because oligonucleotides and viral vectors need specialized clean rooms, tight quality systems, and long release testing. The company’s 2025 scale-up work makes supply reliability a strategic expense, since batch failures or delays can hit both cost and product flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSales, medical affairs, and access support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics spends heavily on specialist sales, medical affairs, and access support because rare-disease drugs need payer coverage, clinician education, and patient help, not mass-market ads. In 2024, selling, general and administrative expense was $1.1 billion, underscoring the recurring cost to protect access and adherence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialist teams drive reimbursement\u003c\/li\u003e\n\u003cli\u003ePatient support improves adherence\u003c\/li\u003e\n\u003cli\u003eRecurring SG\u0026amp;A stays high\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory, safety, and post-market obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor Sarepta Therapeutics, Inc., regulatory and post-market costs stay high after launch because gene therapies need long safety follow-up, often up to 15 years under FDA guidance. That means ongoing pharmacovigilance, REMS-style monitoring, and case review costs that can keep rising as patient numbers grow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e15-year safety follow-up for gene therapy\u003c\/li\u003e\n\u003cli\u003eOngoing pharmacovigilance after launch\u003c\/li\u003e\n\u003cli\u003eHigher burden in rare-disease treatments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta’s Cost Base Is Heavy on R\u0026amp;D and SG\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. cost structure is dominated by R\u0026amp;D, which was about $1.2 billion in 2024, plus high clinical, manufacturing, and regulatory follow-on spend. SG\u0026amp;A was about $1.1 billion in 2024, so access support and specialist selling remain major fixed costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$1.2 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$1.1 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGene therapy follow-up\u003c\/td\u003e\n\u003ctd\u003eUp to 15 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRevenue Streams\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEXONDYS 51 product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEXONDYS 51 is a direct U.S. product-sale revenue stream for Sarepta Therapeutics, Inc., tied to exon 51–eligible Duchenne muscular dystrophy patients and payer coverage. In 2025, it remained one of Sarepta Therapeutics, Inc.’s core marketed products, with demand driven by diagnosed patient access and reimbursement decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVYONDYS 53 product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVYONDYS 53 product sales are revenue from Sarepta Therapeutics, Inc.’s exon 53 Duchenne muscular dystrophy therapy, aimed at the mutation-defined exon 53 patient group. It broadens the Duchenne franchise beyond EXONDYS 51 and helps diversify revenue across a second genotype-linked product line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture gene therapy product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSRP-9001 and SRP-9003 could become future commercial revenue for Sarepta Therapeutics, Inc. if approved and launched, adding high-value gene therapy sales in a market where single-dose therapies can price in the high six-figure to low seven-figure range per patient. This is a key long-term growth stream because even a modest launch can move revenue fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCollaboration and license income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. earns collaboration and license income from biotech partnerships through upfront fees, development funding, and milestone-linked license payments, which helps offset high R\u0026amp;D spend. These deals also let Sarepta share risk while keeping cash coming in from external research programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront cash improves near-term liquidity.\u003c\/li\u003e\n\u003cli\u003eDevelopment funding lowers R\u0026amp;D burden.\u003c\/li\u003e\n\u003cli\u003eLicense income adds non-product revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMilestones and royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. can earn non-product revenue from partner deals through milestone payments when programs hit development, regulatory, or launch steps, plus royalties after a partnered therapy starts selling. This stream is tied to pipeline progress, so it can add cash without direct product sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMilestones: paid on key R\u0026amp;D or approval events\u003c\/li\u003e\n\u003cli\u003eRoyalties: paid after market launch\u003c\/li\u003e\n\u003cli\u003eRevenue rises with partner pipeline success\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta Revenue: U.S. Duchenne Sales Today, Gene Therapy Upside Tomorrow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc.’s 2025 revenue mix still came mainly from U.S. Duchenne product sales, led by EXONDYS 51 and VYONDYS 53, while future upside sits in SRP-9001 and SRP-9003. Partner fees, milestones, and royalties stay a smaller but useful non-product cash stream.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2025\/2026 angle\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEXONDYS 51\u003c\/td\u003e\n\u003ctd\u003eCore U.S. sale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVYONDYS 53\u003c\/td\u003e\n\u003ctd\u003eSecond exon franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSRP-9001 \/ SRP-9003\u003c\/td\u003e\n\u003ctd\u003eFuture gene-therapy sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner income\u003c\/td\u003e\n\u003ctd\u003eFees, milestones, royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234920309001,"sku":"srpt-business-model-canvas","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/srpt-business-model.webp?v=1785732474","url":"https:\/\/dcfanalyst.com\/products\/srpt-business-model-canvas","provider":"DCF Analyst","version":"1.0","type":"link"}